GlassScriptPhysician profile
Camilo F Serrano
NPI 1780744250
$7,289.82
in general payments reported to CMS, 2019-2025
26 companies · $1,674 in 2025
The $1,674 reported for 2025 was more than what 87% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $586 · 2020: $308 · 2021: $482 · 2022: $1,290 · 2023: $1,394 · 2024: $1,556 · 2025: $1,674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,612 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,612.08 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,295.87 | 2020-2025 | Caplyta |
| Abbvie INC. | $815.95 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $789.78 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $685.41 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $605.22 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $511.74 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Janssen Pharmaceuticals, INC | $393.01 | 2019-2025 | Invega, Spravato, Invega Sustenna |
| Axsome Therapeutics, INC. | $264.77 | 2024-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $258.31 | 2019-2025 | Fanapt, Hetlioz |
| Corium, LLC | $228.92 | 2022-2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $225.51 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $196.45 | 2019-2022 | |
| Almatica Pharma LLC | $186.96 | 2022-2025 | Loreev Xr, Gralise, Sertraline Hcl |
| Takeda Pharmaceuticals U.S.A., INC. | $154.56 | 2019-2023 | Trintellix |
| Lundbeck LLC | $150.87 | 2019-2025 | Rexulti |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $130.25 | 2021-2025 | Qelbree, Qelbree |
| Allergan, INC. | $92.85 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $69.08 | 2019-2024 | |
| Idorsia Pharmaceuticals US INC | $63.08 | 2023-2025 | Quviviq, Quviviq |
| Avanir Pharmaceuticals, INC. | $39.34 | 2019 | |
| Eisai INC. | $28.41 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $27.47 | 2022 | |
| Adlon Therapeutics L.P. | $27.28 | 2021 | |
| Neuronetics, INC. | $21.18 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $13.96 | 2023 | |
| Indivior INC. | $13.59 | 2024 | Perseris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Camilo Serrano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.